SELECT
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is SELECT?
SELECT ran semaglutide 2.4 mg against placebo in 17,604 people who were overweight or obese and already had cardiovascular disease, none of them diabetic (Lincoff et al., NEJM 2023).
Major adverse cardiovascular events fell 20% (HR 0.80, 95% CI 0.72–0.90). That result is why the drug is now argued about as cardiac prevention instead of cosmetics.
Read more:
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where SELECT comes up on this site
On GLP Watchdog, SELECT comes up in 7 research articles and 1 tool.
Research that discusses it
- GLP-1 Bowel Obstruction and Ileus: Label Warning and Evidence Review
- Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show
- Does Semaglutide Slow Aging? What the Longevity Evidence Shows
- Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started
- The Biggest Number Is the Weakest
- Semaglutide and Days Spent in Hospital
- All 7 articles are on the research page
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers